Vital-IT was built around a simple but consequential question: what if we could identify patient frailty risk earlier…and, do something about it before outcomes worsen?
Frailty is one of the most powerful (and expensive) predictors of poor health outcomes in America. Studies have shown that frail patients experience significantly higher rates of complications, longer hospital stays, increased readmissions, and greater reliance on post-acute care. As the U.S. population ages, frailty-related costs are estimated to account for tens of billions of dollars annually, driven not by the complexity of procedures themselves, but by avoidable downstream consequences when patients are insufficiently prepared for care. When frailty goes unrecognized, healthcare becomes reactive and costly. When it is identified early, care can be proactive, targeted, and more efficient.
Founded in Omaha, Vital-IT develops technology designed to bring that early insight into routine clinical practice. The company focuses on objectively assessing frailty, a condition characterized by diminished strength, mobility, and physiological resilience that is often overlooked or informally judged in clinical settings. Despite its impact on outcomes, frailty has historically lacked a standardized, scalable method of measurement in everyday care.
Vital-IT addresses that gap by turning frailty into a consistent clinical signal. Its platform captures validated measures — including grip strength and walking speed — during patient intake and delivers results securely to care teams. The process is designed to integrate seamlessly into existing workflows, replacing subjective assessments with objective data that clinicians can act on before surgery, hospitalization, or major intervention occurs.
The company was founded by Dr. Jason Johanning, a vascular surgeon who spent years seeing the consequences of missed or misunderstood patient risk. In practice, frailty often revealed itself only after complications emerged — when recoveries slowed, lengths of stay increased, and costs escalated for both patients and providers. Johanning recognized that earlier identification could change not only outcomes, but the economics of care.
Crucially, Vital-IT was never intended as a gatekeeping tool. Johanning has emphasized that identifying frailty should not be used to deny treatment. Instead, the insight allows clinicians to intervene earlier — surrounding patients with appropriate resources, prehabilitation, and tailored care pathways to improve outcomes. Frailty assessment, in this framing, becomes a mechanism for better care, not less care.
That perspective aligns with broader shifts in healthcare reimbursement. As payment models increasingly reward value over volume, health systems are incentivized to reduce complications, readmissions, and unnecessary utilization. Tools that improve risk stratification upstream can dramatically influence costs downstream, fewer ICU days, smoother recoveries, and better alignment between treatment intensity and patient capacity.
Only later in Vital-IT’s story does its academic foundation fully emerge. Johanning is also a professor of surgery at the University of Nebraska Medical Center (UNMC), where years of research into frailty and surgical outcomes laid the groundwork for the platform’s development. That academic rigor helped propel Vital-IT toward FDA clearance and real-world deployment, bridging research and operational care.
Vital-IT represents a growing class of healthtech companies focused less on disruption for its own sake and more on precision, evidence, and measurable impact. By addressing frailty, one of the most expensive and under-recognized drivers of poor outcomes, the company underscores a critical truth: getting care right early isn’t just clinically smarter. It’s economically essential.
